Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000–2016

@article{Farhat2018TrendsIC,
  title={Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000–2016},
  author={Nawal Farhat and Nisrine Haddad and James A.G. Crispo and Nicholas Birkett and Douglas S. McNair and Franco Momoli and Shi Wu Wen and Donald R. Mattison and Daniel Krewski},
  journal={European Journal of Clinical Pharmacology},
  year={2018},
  volume={75},
  pages={227-235}
}
PurposeThe US Food and Drug Administration (FDA) issued three safety announcements between January 2009 and October 2010 warning against concomitant use of clopidogrel and proton pump inhibitors (PPIs) due to a potential drug-drug interaction that may attenuate clopidogrel’s antiplatelet activity. This primary objective of this study was to examine trends in concomitant clopidogrel/PPI use among acute coronary syndrome (ACS) inpatients in the US between 2000 and 2016, in relation to the FDA… 
Concomitant use of drugs known to cause interactions with oral antiplatelets—polypharmacy in acute coronary syndrome outpatients in Finland
TLDR
Warfarin and ibuprofen were the most commonly used concomitant medications causing pharmacodynamic interactions and potentially increasing the risk of bleeding in OAP-treated patients.
Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
TLDR
The use of clopidogrel either alone or in combination is quite widespread, in particular among the elderly and persons with diabetes, which supports the emerging need of accessing and accounting for not only DDI but also for applying PGx-guided drug therapy in clinical decision making for antiplatelet therapy.
The Clinical Impact of Proton Pump Inhibitors When Co-Administered With Dual Antiplatelet Therapy in Patients Having Acute Myocardial Infarction With Low Risk of Gastrointestinal Bleeding: Insights From the China Acute Myocardial Infarction Registry
TLDR
PPIs did not show an extra gastrointestinal protective effect, while an increased risk of stroke was observed during the 2-year follow-up, and PPI use is prevalent in DAPT patients with low GIB risk.
Cost-Effectiveness and Cost–Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran
TLDR
Abiding by the WHO threshold for cost-effectiveness, the concomitant use of pantoprazole and clopidogrel can be considered cost-effective compared to the simultaneous use of clopIDogrel and omeprazole.
The Association between Co-Administration of Omeprazole and Clopidogrel and Cardiovascular Outcomes
TLDR
Addition of omeprazole to clopidogrel may be associated with increased incidence of negative clinical outcomes, including death and MACE, and underscore the need for conduction of prospective randomized controlled trials.
Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases
TLDR
Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses.
Metabolomics Analysis of the Effect of Hydrogen-Rich Water on Myocardial Ischemia-Reperfusion Injury in Rats
TLDR
Hydrogen-rich water regulates the metabolic imbalance that could change MIRI myocardial tissue metabolism, and alleviate ischemia-reperfusion injury in isolated hearts of rats through multiple signaling pathways.
Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines
TLDR
The only large international randomized control trial (RCT), Clopidogrel and the Optimization of Gastrointestinal Events Trial (COGENT), shows robust evidence that PPIs are a safe and effective method to reduce the risk of bleeding in patients on DAPT.
Letter: proton pump inhibitors and risk of myocardial infarction
TLDR
It is reported that proton pump inhibitors did not increase the risk of myocardial infarction in the first decade after treatment initiation in comparison with H2receptor antagonists, and this study has strengths, but there are some concerns.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Trends in the coprescription of proton pump inhibitors with clopidogrel: an ecological analysis.
TLDR
In 2009, the prescribing of PPIs with clopidogrel changed substantially in Ontario, with pantoprazole rapidly becoming the most commonly prescribed agent in its class.
Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication
TLDR
The FDA Safety Communication resulted in a reduction in the number of patients undergoing combination therapy; however approximately one-third of patients still used combination therapy post-communication.
Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar
TLDR
The rate of PPI co-prescribing with DAPT in the population studied was relatively high, and PPI prescribing was significantly predicted by nationality and not having diabetes, which is significantly less likely to be prescribed PPIs upon discharge compared to those with no history of diabetes.
Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel – proton pump inhibitor interaction
TLDR
Assessment of the association between various safety statements and prescription behavior for gastroprotective drugs in naïve patients in the Netherlands during the years 2008–2011 found that advice via an adjusted statement was to avoid (es)omeprazole placed patients at risk for cardiovascular events.
Concomitant use of drugs known to cause interactions with oral antiplatelets—polypharmacy in acute coronary syndrome outpatients in Finland
TLDR
Warfarin and ibuprofen were the most commonly used concomitant medications causing pharmacodynamic interactions and potentially increasing the risk of bleeding in OAP-treated patients.
Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review
TLDR
With the accumulating evidence from better designed, prospective clinical studies, an adverse effect of PPI use on clinical outcome in patients on clopidogrel cannot be substantiated and the validity of conclusions based on quantitative analyses of predominantly non-randomised data is challenged.
Trends in inpatient antiparkinson drug use in the USA, 2001–2012
TLDR
Dopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing, andAntiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes
TLDR
There is still a high rate of use of clopidogrel, despite guidelines recommendations, and the analyses showed a trend toward the use of ticagrelor, highlighting a therapeutic inertia with considerable gap between evidence-based clinical guidelines and daily clinical practice.
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta‐analysis
TLDR
Concomitant PPI use might be associated with an increased risk of cardiovascular events but does not influence the risk of death, and two studies indicate that PPIs have a negative effect irrespective of clopidogrel exposure.
...
...